MICS+aspheric IOL = fewer corneal changes

Article

Microincision cataract surgery (MICS) with implantation of an aspheric intraocular lens (IOL) through a 1.8 mm incision can minimize surgically-induced corneal and ocular aberrations and improve optical performance, according to a French study.

Microincision cataract surgery (MICS) with implantation of an aspheric intraocular lens (IOL) through a 1.8 mm incision can minimize surgically-induced corneal and ocular aberrations and improve optical performance, according to a French study.

Alexandre Denoyer and co-workers from Bretonneau University Hospital, France evaluated the postoperative corneal and ocular aberrations of 20 subjects following MICS with implantation of the aspheric MI60 IOL (Bausch & Lomb) through a 1.8 mm incision in one eye and through a 2.8 mm incision in the other eye.

The researchers found that changes in the corneal topography and aberrations were lower in the MICS group than in the other eye (p<0.05), as were the total ocular wavefront aberrations (p<0.05). Best corrected visual acuity and subjective visual comfort were similar in both groups.

Dr Denoyer concluded that MICS with implantation of an aspheric IOL can help minimize surgically-induced corneal changes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.